Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9770407 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(5 years from now) | |
US9629797 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(5 years from now) | |
US8410077 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
US7635773 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
US9750822 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
US9493582 | LUNDBECK PHARMS LLC | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(9 years from now) | |
US11529357 | LUNDBECK PHARMS LLC | Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine |
Jan, 2040
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Oct 7, 2023 |
Market Authorisation Date: 07 October, 2016
Treatment: Replacement therapy for oral carbamazepine in adults with partial seizures with complex symptomatology; Replacement therapy for oral carbamazepine in adults with generalized tonic-clonic seizures; Rep...
Dosage: SOLUTION;INTRAVENOUS
25
United States
10
Japan
6
China
5
European Union
4
Australia
4
Korea, Republic of
4
Canada
4
Russia
4
Mexico
2
Israel
2
New Zealand
2
Spain
2
Hong Kong
2
Brazil
1
EA
1
Denmark
1
Cyprus
1
Portugal
1
Poland
1
Slovenia
1
South Africa
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6977253 | VALIDUS PHARMS | Methods for the treatment of bipolar disorder using carbamazepine |
May, 2024
(11 months from now) |
Market Authorisation Date: 10 December, 2004
Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
3
United States
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic